Abstract B21: Depression and quality of life in breast cancer survivors: 6–13 years postchemotherapy

Abstract

Abstract Background: Advances in breast cancer treatment have markedly prolonged survival time. This study examines the prevalence of and risk factors for depression and its impact on quality of life in breast cancer patients 6–13 years post-treatment. Method: The Patient Health Questionnaire (PHQ-8) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were mailed to assess depression and quality of life, respectively, in breast cancer patients who participated in clinical trials for paclitaxel chemotherapy treatment between 1994 and 2001. Results: Two hundred forty patients participated (56% response rate). The years since treatment were between 6–13 years (mean= 7.9 and median=8). The mean score on the PHQ-8 scale was 4 points (SD=4.8; median=2.0) which decreased by years since treatment (Kruskal-Wallis, p< 0.001). Prevalence of depression (PHQ score ≥10) was 16%. Reports of depression decreased every year from treatment by as much as 30%. Depression had a negative impact on quality of life measures (function, symptoms, financial and global health), irrespective of years from treatment. Logistic regression showed that younger age (OR age in years= 0.92; 95% Confidence Interval [C.I.] = 0.86, 0.99; p<0.02), rheumatoid arthritis (OR=8.4; 95%C.I.=1.3–57.4; p<0.03) and years from treatment (OR=0.70; 95% C.I.=0.46–0.99; p<0.05) were significant predictors of depression. Conclusion: While reports of depression decreased over the survival period, it remains a significant health concern for breast cancer survivors. The results suggest the need to monitor patients and provide resources for monitoring and treatment of depression within the clinical oncology setting. Citation Information: Cancer Prev Res 2010;3(1 Suppl):B21.